The vaccine, developed by researchers at the University of Colorado, USA, is made of a dry powder dispensed in the mouth using a small plastic sack.
It is designed to target the respiratory tract where the measles virus originates. It costs around the same as an injectable form of the vaccine.
The researchers hope that the inhalant vaccine will end the use of needles and syringes, which can frighten children and can transmit diseases.
According to the World Health Organisation, measles is one of the leading causes of death among young children. In 2008 an estimated 164,000 children worldwide died of measles.
Phase one of clinical trials to test the safety of the inhalant vaccine will start this summer in Pune, India, and involve around 180 people.
Register now to continue reading
Thank you for visiting Nursery World and making use of our archive of more than 35,000 expert features, subject guides, case studies and policy updates. Why not register today and enjoy the following great benefits:
What's included
-
Free access to 4 subscriber-only articles per month
-
Unlimited access to news and opinion
-
Email newsletter providing activity ideas, best practice and breaking news
Already have an account? Sign in here
